Protective effect of influenza vaccine in Brazilian patients hospitalised for severe acute respiratory infection, 2023-2025
- 1Universidade Federal de Santa Catarina, Brazil
Abstract
IntroductionDespite a significant increase in influenza burden in Brazil in 2025, influenza vaccine effectiveness has not included the key end-of-winter period so far. Methods: The key exposure measure was the number of trivalent influenza vaccine doses received within a calendar year. In-hospital mortality and length of stay, use of the intensive care unit (ICU), and ICU stay were outcome measures. Secondary data from January 2003 to October 2025 were retrieved and analysed by Poisson regression.
ResultsInfluenza vaccine uptake among SARI-hospitalised patients dropped from about 70% in 2023 to a 40-50% level in 2024 and 2025. A single vaccine dose reduced outcomes by 10-13% compared to unvaccinated patients. Two doses per year significantly reduced mortality (32%), ICU admissions (52%), and ICU stay (28%).
ConclusionTwo doses of influenza vaccine were moderately effective in decreasing in-hospital mortality and stay among SARI-hospitalised influenza patients. Including 50-59-year-olds in a priority vaccination group may significantly reduce influenza-related adverse outcomes.
Related
- Machine-learning model for distinguishing cytomegalovirus infection status in hospitalised patients with systemic lupus erythematosus: a retrospective cohort study with temporal validation.
- Development of a human respiratory tract effector cell-mediated antiviral assay using blood and airway immune cells from individuals previously hospitalised with COVID-19
- Global Protective Ventilator Settings Are Not Regional Protection: A Compartment-Resolved Framework for Personalizing Mechanical Ventilation in Acute Respiratory Distress Syndrome
- Evaluation of the One-Step Multiplex Real-Time Reverse Transcription-PCR ProFlu-1 Assay for Detection of Influenza A and Influenza B Viruses and Respiratory Syncytial Viruses in Children
- Socioeconomic and clinical factors associated with odontogenic infection types among hospitalised patients in Periurban Ghana
BibTeX
@misc{kupek2026protective,
title = {{Protective effect of influenza vaccine in Brazilian patients hospitalised for severe acute respiratory infection, 2023-2025}},
author = {E. Kupek},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.15.26362995},
url = {https://www.medrxiv.org/content/10.64898/2026.09.15.26362995v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Protective effect of influenza vaccine in Brazilian patients hospitalised for severe acute respiratory infection, 2023-2025
AU - E. Kupek
PY - 2026
DA - 2026/09/15
PB - medRxiv
DO - 10.64898/2026.09.15.26362995
UR - https://www.medrxiv.org/content/10.64898/2026.09.15.26362995v1
AB - IntroductionDespite a significant increase in influenza burden in Brazil in 2025, influenza vaccine effectiveness has not included the key end-of-winter period so far. Methods: The key exposure measure was the number of trivalent influenza vaccine doses received within a calendar year. In-hospital mortality and length of stay, use of the intensive care unit (ICU), and ICU stay were outcome measures. Secondary data from January 2003 to October 2025 were retrieved and analysed by Poisson regression. ResultsInfluenza vaccine uptake among SARI-hospitalised patients dropped from about 70% in 2023 to a 40-50% level in 2024 and 2025. A single vaccine dose reduced outcomes by 10-13% compared to unvaccinated patients. Two doses per year significantly reduced mortality (32%), ICU admissions (52%), and ICU stay (28%). ConclusionTwo doses of influenza vaccine were moderately effective in decreasing in-hospital mortality and stay among SARI-hospitalised influenza patients. Including 50-59-year-olds in a priority vaccination group may significantly reduce influenza-related adverse outcomes.
ER -